/
Oncology
High Grade Glioma
17
Pipeline Programs↗
15
Active Trials↗
11
Companies Involved↗
High Grade Glioma is an emerging landscape with 17 programs across 11 companies. The most active players are Beijing Bio-Targeting Therapeutics Technology Co., Ltd.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 110
Phase 25
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
9 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 82% of 17 pipeline programs.
Analysis
Trial Status
17
clinical trials
Recruiting10 · 59%
Not yet recruiting4 · 24%
Completed2 · 12%
Active, not recruiting1 · 6%
Clinical Trials
Trial Activity
17 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)